Blog Posts

電子煙5000口可以抽多久?

Posted by dajksdhj21 on September 19, 2024 at 10:23pm 0 Comments

電子煙的使用時間取決於多種因素,包括吸煙頻率、每口吸入的量以及設備的電池壽命等。一般來說,5000口的電子煙可以使用數天到數周,具體時間因人而異。如果您每天吸200口,那麼5000口大約可以使用25天。







電子菸5000口可以抽多久?







電子煙的使用時間主要取決於您每天吸煙的頻率。例如,如果您每天吸200口,那麼5000口的電子煙可以使用約25天(5000口 ÷ 200口/天 =…

Continue

電子煙40mg是多少尼古丁?

Posted by dajksdhj21 on September 19, 2024 at 10:22pm 0 Comments

電子煙煙液的尼古丁含量通常以每毫升(mg/ml)為單位表示。40mg的尼古丁含量意味著每毫升電子煙液中含有40毫克的尼古丁。為了更好地理解這個概念,我們可以將其與傳統香煙進行比較。

傳統香煙與電子菸的尼古丁含量比較

一根普通香煙大約含有12毫克的尼古丁,但在吸煙過程中,人體實際攝入的尼古丁量約為1-2毫克。因此,如果您每天吸20根香煙,您實際攝入的尼古丁大約是20-40毫克。

溫馨提示:購買時及時聯繫電子煙專賣店客服反饋,以確保買到喜歡的口味和安全使用電子煙。

電子煙…

Continue

飛機上可以帶電子煙嗎?

Posted by dajksdhj21 on September 19, 2024 at 10:09pm 0 Comments

飛機上可以攜帶電子煙,電子煙及其配件(尤其是包含鋰電池的部分)不能放在託運行李中,而必須隨身攜帶。以下是一些關鍵原因和相關規定:







🟢禁止託運的原因



鋰電池風險:電子菸通常包含鋰離子電池,這種電池在某些情況下可能會過熱、起火甚至爆炸。將鋰電池放在託運行李中,如果發生問題,機組人員無法及時處理,因此航空公司通常要求將其放在隨身行李中,以便在緊急情況下能夠迅速應對。



國際航空運輸協會(IATA)規定:根據IATA的危險品規定,鋰電池應隨身攜帶,而不是託運。這些規定旨在確保飛行安全,航空公司通常會嚴格遵守這些規定。



🟢具體規定…

Continue

Stepping into the Future: The Role of Technology in Footwear Evolution

Posted by freeamfva on September 19, 2024 at 9:31pm 0 Comments

Stepping into the Future: The Role of Technology in Footwear Evolution



Footwear has come a long way from its humble beginnings as a basic necessity for protecting our feet. Today, technology plays a pivotal role in the evolution of footwear, driving innovation and transforming the industry. This article explores how technological advancements have revolutionized footwear design, production, and functionality, making shoes more than just a fashion statement.



Smart… Continue

Benign Prostatic Hyperplasia Treatment Market: Increasing prevalence of benign prostatic hyperplasia

Benign prostatic hyperplasia (BPH) is a common condition among older men where the prostate gland grows in size and puts pressure on the urethra, leading to difficulty urinating. BPH is a progressive condition, and if left untreated, it can cause severe urinary symptoms, bladder damage, and even kidney damage.
The growth of Benign Prostatic Hyperplasia Treatment Market is driven by the increasing prevalence of benign prostatic hyperplasia, the rising preference for minimally invasive surgeries, increasing obesity rate, and investments, funds, and grants for research in the field of BPH treatment.
The Benign prostatic hyperplasia treatment market is projected to reach USD 14.1 billion by 2026 from USD 10.8 billion in 2021, at a CAGR of 5.3% from 2021 to 2026.
Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=198000374
Scope of the Report
This research report categorizes the benign prostatic hyperplasia treatment market into the following segments and subsegments:
Benign Prostatic Hyperplasia Treatment Market by Type
• Drug Treatment
• Alpha Blockers
o Alfuzosin
o Doxazosin
o Tamsulosin
o Silodosin
o Other Alpha Blockers
• 5-Aplha Reductase Inhibitors
o Finasteride
o Dutasteride
• Other Drug Classes
• Surgical Treatment
• Transurethral Resection of the Prostate (TURP)
• Transurethral Microwave Thermotherapy (TUMT)
• Transurethral Needle Ablation of the Prostate (TUNA)
• Laser Therapy
• Prostatic Stenting
• UroLift Therapy
• Rezûm Therapy
• Other Surgeries
Benign Prostatic Hyperplasia Treatment Market, by Region
• North America
o US
o Canada
• Europe
o Germany
o UK
o France
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Rest of Asia Pacific
Market Segmentation:-
Based on the type, the BPH treatment market is segmented into drug treatment and surgical treatment. Drug treatment is the largest and the fastest-growing segment in this market. This can primarily be attributed to the use of medications as the first line of treatment among men with mild to moderate symptoms of BPH.
Based on the end user, the market is segmented into home healthcare and hospitals & clinics. In 2019, home healthcare accounted for the largest share of this market, as most patients are prescribed medications over surgery. Patients are also advised to continue taking medications for a few weeks post-surgery and may even require catheters for a few days. As a result, the emphasis in his market is skewed toward home healthcare over hospital care.
Regional Analysis:
On the basis of region, the benign prostatic hyperplasia treatment market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. In 2019, North America commanded the largest share of the benign prostatic hyperplasia treatment market. The large share of this market segment can be attributed to the rising geriatric and obese population and the availability of research funding are the major factors driving the market growth. Initiatives by key players are also expected to contribute to the market.
Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=198000374
Recent Developments
• In 2021, In January 2021, PHAREX Health Corporation in partnership with the Philippine Urological Association (PUA), launched Pharex Tamsulosin for BPH treatment.
• In 2020, UroLift launched Advanced Tissue Control (ATC) System
• In 2020, Asahi Kasei Pharma obtained Chinese approval for Flivas (naftopidil).
• In 2019, Alembic received approval from the US FDA for its Abbreviated New Drug Application (ANDA) for Silodosin Capsules 4 mg and 8 mg
• In 2018, NxThera’s Rezûm system, a minimally invasive therapy (MIT) for patients with BPH, was included under Boston’s Urology and Pelvic Health business.
• In 2017, Eli Lilly and Company entered into a settlement agreement with generic companies to resolve pending patent litigation.

Top Key Players: -
The major players operating in this market are Boston Scientific Corporation (US), Coloplast Group (Denmark), Teleflex Incorporated (US), Olympus Corporation (Japan), GlaxoSmithKline PLC (UK), Eli Lilly (US), Pfizer, Inc. (US), Abbott (US), Asahi Kasei Corporation (Japan), Merck & Co., Inc. (US), Astellas Pharma Inc. (Japan), Allergan plc (Ireland), Alembic (India), IPG Photonics Corporation (US), Richard Wolf GmbH (Germany), Unilab, Inc. (Philippines), Pharex Health Corporation (Philippines), Biolitec AG (Austria), Urologix, LLC (US), Advin Health Care (India), Medifocus, Inc. (Canada), Asclepion Laser Technologies GmbH (Germany), Pnn Medical A/S (Denmark), Surgical Lasers Inc. (Canada). Quanta Systems (Italy), Allium Ltd. (Israel), Lumenis Ltd. (Israel), KARL STORZ SE & Co. KG (Germany), and SRS Medical (US).
Conclusion
In conclusion, the global market for BPH treatment is expected to grow in the coming years, driven by the increasing prevalence of BPH among the aging population and the demand for minimally invasive procedures. With the advent of new and innovative treatment options, the BPH treatment market is poised for further growth and development in the future.

Views: 2

Comment

You need to be a member of On Feet Nation to add comments!

Join On Feet Nation

© 2024   Created by PH the vintage.   Powered by

Badges  |  Report an Issue  |  Terms of Service